Stocks Health care AMPH
NASDAQ · Health careAmphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. brought in $745.8M of revenue over the twelve months to September 30, 2026, up 3.1% from a year earlier. Net income was $99M, a net margin of 13.3%. Operating cash flow minus capital spending left $121.2M of free cash flow in fiscal 2025. At September 30, 2026 it held $204.6M in cash against $613M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Amphastar Pharmaceuticals, Inc.
- Net worth
- Amphastar Pharmaceuticals, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $814.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $719.9M (-1.7% year on year), with net income of $98.1M. Over the 12 months to September 30, 2026: revenue $745.8M, net income $99M.
- Cash flow
- In fiscal 2025 operations brought in $156.1M of cash; after $34.9M of capital spending, free cash flow was $121.2M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Amphastar Pharmaceuticals, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Amphastar Pharmaceuticals, Inc. does
Amphastar Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AMPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $719.9M | $98.1M | $2.03 | $121.2M |
| 2024 | $732M | $159.5M | $3.06 | $172.3M |
| 2023 | $644.4M | $137.5M | $2.60 | $145.3M |
| 2022 | $499M | $91.4M | $1.74 | $65.1M |
| 2021 | $437.8M | $62.1M | $1.25 | $70.5M |
| 2020 | $349.8M | $1.4M | $0.03 | $23.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AMPH ranks in Health care
Latest SEC filings
What Amphastar Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 8.2% to $207.6M versus the same quarter last year; diluted EPS $0.87 versus $0.37.
- November 5, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.4% to $183.9M versus the same quarter last year; diluted EPS $0.67 versus $0.64.
- August 6, 2026
- July 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 13, 2026
- July 8, 2026Other event 8-K
- June 3, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was flat at $171.2M versus the same quarter last year; diluted EPS $0.14 versus $0.51.
- May 7, 2026
What is AMPH worth? A DCF from its reported cash flow
Insider trades
What the people running Amphastar Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (74%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Peters William JCFO, EVP & TREASURER, Director | Exercised options | 11,000 | $197.9K |
| November 5, 2026 | Peters William JCFO, EVP & TREASURER, Director | Soldpre-planned (10b5-1) | 12,631 | $366.2K |
| November 4, 2026 | Peters William JCFO, EVP & TREASURER, Director | Exercised options | 16,000 | $208.5K |
| November 4, 2026 | Peters William JCFO, EVP & TREASURER, Director | Soldpre-planned (10b5-1) | 16,000 | $448.5K |
| September 21, 2026 | Peters William JCFO, EVP & TREASURER, Director | Soldpre-planned (10b5-1) | 4,139 | $103.5K |
| September 16, 2026 | Zhou RongSENIOR EVP, PRODUCTION CENTER | Exercised options | 10,000 | $133.5K |
| September 16, 2026 | Zhou RongSENIOR EVP, PRODUCTION CENTER | Sold | 10,000 | $239.4K |
| September 2, 2026 | Zhou RongSENIOR EVP, PRODUCTION CENTER | Sold | 3,187 | $75.3K |
Who owns AMPH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Jack Y. Zhang13G, passive with 2 related filers | 24.8% | February 7, 2025 |
| Dimensional Fund Advisors LP13G, passive | 5.2% | July 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 210 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,224,934 | -196,409 |
| Dimensional Fund Advisors LP | 2,305,107 | +277,160 |
| State Street Corp | 1,642,126 | +34,611 |
| Vanguard Capital Management LLC | 1,481,952 | -61,703 |
| American Century Companies Inc | 1,176,626 | +159,088 |
| Marshall Wace, Llp | 1,066,322 | +40,682 |
| Geode Capital Management, LLC | 969,840 | -6,810 |
| Fuller & Thaler Asset Management, Inc. | 949,238 | -445,901 |
| D. E. Shaw & Co., Inc. | 887,048 | +221,506 |
| Vanguard Portfolio Management LLC | 809,568 | +21,752 |
| Renaissance Technologies LLC | 525,100 | -28,800 |
| Goldman Sachs Group Inc | 505,360 | +175,972 |
| Systematic Financial Management LP | 437,384 | -15,514 |
| Morgan Stanley | 434,840 | +14,503 |
| UBS Group AG | 393,110 | -27,153 |
| Denali Advisors LLC | 375,965 | +109,500 |
| Northern Trust Corp | 370,991 | -1,288 |
| Bridge City Capital, LLC | 338,708 | +3,603 |
| Charles Schwab Investment Management Inc | 310,178 | -10,861 |
| Bridgeway Capital Management, LLC | 298,954 | -31,503 |
Insiders
12 insiders reported holding 5,239,641 shares in total, about $153.9M at the last price.
| Holder | Shares |
|---|---|
| Zhang Jack Y.CEO & CHIEF SCIENTIFIC OFFICER, Director, 10% owner | 4,235,1771,245,125 held indirectly |
| Zhou RongSENIOR EVP, PRODUCTION CENTER | 344,197 |
| Peters William JCFO, EVP & TREASURER, Director | 167,076 |
| Lee HowardDirector | 159,350 |
| Liawatidewi YakobEVP CORP ADMIN CENTER, Director | 121,892 |
| Petersen Floyd F.Director | 71,368 |
| Zasloff Michael ADirector | 37,667 |
| Gerst Diane G.Director | 31,899 |
| Prins Richard KDirector | 29,625 |
| Deflin GayleDirector | 19,057 |
Questions about AMPH
What does Amphastar Pharmaceuticals, Inc. do?
Amphastar Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as AMPH. Its shares trade on NASDAQ under the ticker AMPH.
What is Amphastar Pharmaceuticals, Inc.'s net worth?
Amphastar Pharmaceuticals, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $814.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Amphastar Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $99M on revenue of $745.8M, a net margin of 13.3%.
How much revenue does Amphastar Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Amphastar Pharmaceuticals, Inc. reported revenue of $745.8M. That is 3.1% more than a year earlier.
When did Amphastar Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Amphastar Pharmaceuticals, Inc.'s next earnings report?
Amphastar Pharmaceuticals, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AMPH with
Follow AMPH
Get an email when Amphastar Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Amphastar Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.